What to expect in the Trevi Therapeutics, Inc. interview process

Based on publicly available sources, Trevi Therapeutics, Inc. is a small, clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut, with an additional office in Sandy Hook. Founded in 2011 and publicly traded on Nasdaq under the ticker TRVI, the company operates with a lean workforce numbering between roughly 26 and 37 employees.

Public data indicates that the company is intensely focused on the development and commercialization of its primary investigational therapy, Haduvio (oral nalbuphine extended-release), targeting chronic cough conditions associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. Executive leadership includes Co-Founder, CEO, and President Jennifer L. Good, alongside a compact team of senior executives managing development, commercial, scientific, and financial operations. Given its micro-size, clinical-stage status, and focus on respiratory and neurological-mediated conditions, prospective employees should expect a high-visibility, fast-paced environment typical of small biotech research firms, where individual contributions directly impact clinical milestones and ongoing trial execution.